Table 3.
Hazard ratios (95% confidence intervals) of venous thromboembolism (VTE) by quartiles or SD increment of high molecular weight kininogen and prekallikrein, ARIC, 1993–95 through 2015
| Quartiles |
|||||
|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Per SD increment2 |
|
| High molecular weight kininogen, μg/mL | 2.08−19.11 | 19.12−22.66 | 22.67−26.76 | 26.77−58.57 | |
| n at risk | 983 | 983 | 984 | 983 | 3,933 |
| Incident VTE, n | 172 | 161 | 141 | 138 | 612 |
| Model 1 HR (95% CI) | 1 (Reference) |
0.91 (0.72−1.15) | 0.85 (0.67−1.08) | 0.79 (0.62−1.01) | 0.89 (0.82−0.97) |
| Model 2 HR (95% CI) | 1 (Reference) |
0.90 (0.71−1.14) | 0.84 (0.66−1.07) | 0.77 (0.60−0.99) | 0.88 (0.81−0.97) |
| Model 3 HR (95% CI)1 | 1 (Reference) |
0.93 (0.72−1.21) | 0.79 (0.60−1.04) | 0.68 (0.51−0.90) | 0.83 (0.75−0.92) |
| Model 4 HR (95% CI)1 | 1 (Reference) |
0.93 (0.71−1.21) | 0.80 (0.61−1.06) | 0.67 (0.50−0.90) | 0.83 (0.75−0.92) |
| Prekallikrein, μg/mL | 2.08−10.59 | 10.60−12.80 | 12.81−15.70 | 15.71−95.79 | |
| n at risk+ | 983 | 983 | 985 | 982 | 3,933 |
| Incident VTE, n | 156 | 147 | 163 | 146 | 612 |
| Model 1 HR (95% CI) | 1 (Reference) |
0.96 (0.75−1.22) | 1.17 (0.92−1.49) | 0.99 (0.77−1.27) | 1.00 (0.91−1.09) |
| Model 2 HR (95% CI) | 1 (Reference) |
0.97 (0.76−1.24) | 1.14 (0.89−1.46) | 0.95 (0.73−1.23) | 0.99 (0.91−1.09) |
| Model 3 HR (95% CI)1 | 1 (Reference) |
1.03 (0.78−1.36) | 1.20 (0.91−1.59) | 1.05 (0.79−1.41) | 0.95 (0.86−1.06) |
| Model 4 HR (95% CI)1 | 1 (Reference) |
1.03 (0.78−1.36) | 1.18 (0.89−1.57) | 1.04 (0.78−1.40) | 0.95 (0.85−1.05) |
Model 1: Adjusted for age, race, and sex
Model 2: Adjusted for age, race, sex-hormone replacement therapy, weight, height, diabetes, smoking status, systolic blood pressure, antihypertensive medications, and estimated glomerular filtration rate
Model 3: Model 2 + adjustment for factor XI, log(D-dimer), and weighted genetic risk score (F5, F2, ABO, F11, FGG variants).
Model 4: Model 3 + adjustment for factor VIII, activated partial thromboplastin time, protein C, and Von Willebrand factor.
Models 3 and 4 have a reduced sample size of 3,352 at risk and 514 VTE events due to missing values.
Standard deviation increments were 6.4 μg/mL for HK and 9.1 μg/mL for prekallikrein.
Abbreviations: ARIC = Atherosclerosis Risk in Communities; CI = confidence interval; HK = high molecular weight kininogen; HR = hazard ratio; SD= standard deviation; VTE = venous thromboembolism